No Cover Image

Journal article 674 views 871 downloads

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, paralle... / Vanita R Aroda, Steve Bain, Bertrand Cariou, Milivoj Piletič, Ludger Rose, Mads Axelsen, Everton Rowe, J Hans DeVries

The Lancet Diabetes and Endocrinology, Volume: 5, Issue: 5, Pages: 355 - 366

Swansea University Author: Steve Bain

Published in: The Lancet Diabetes and Endocrinology
ISSN: 22138587
Published: 2017
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa31639
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2017-01-18T14:53:38Z
last_indexed 2020-07-14T12:55:22Z
id cronfa31639
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2020-07-14T12:32:18.7868776</datestamp><bib-version>v2</bib-version><id>31639</id><entry>2017-01-18</entry><title>Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2017-01-18</date><deptcode>BMS</deptcode><abstract/><type>Journal Article</type><journal>The Lancet Diabetes and Endocrinology</journal><volume>5</volume><journalNumber>5</journalNumber><paginationStart>355</paginationStart><paginationEnd>366</paginationEnd><publisher/><issnPrint>22138587</issnPrint><keywords/><publishedDay>31</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2017</publishedYear><publishedDate>2017-05-31</publishedDate><doi>10.1016/S2213-8587(17)30085-2</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2020-07-14T12:32:18.7868776</lastEdited><Created>2017-01-18T08:25:28.4206481</Created><path><level id="1">Swansea University Medical School</level><level id="2">Medicine</level></path><authors><author><firstname>Vanita R</firstname><surname>Aroda</surname><order>1</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>2</order></author><author><firstname>Bertrand</firstname><surname>Cariou</surname><order>3</order></author><author><firstname>Milivoj</firstname><surname>Pileti&#x10D;</surname><order>4</order></author><author><firstname>Ludger</firstname><surname>Rose</surname><order>5</order></author><author><firstname>Mads</firstname><surname>Axelsen</surname><order>6</order></author><author><firstname>Everton</firstname><surname>Rowe</surname><order>7</order></author><author><firstname>J Hans</firstname><surname>DeVries</surname><order>8</order></author></authors><documents><document><filename>0031639-18012017083234.pdf</filename><originalFilename>Aroda2017.pdf</originalFilename><uploaded>2017-01-18T08:32:34.3230000</uploaded><type>Output</type><contentLength>999657</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><embargoDate>2017-07-23T00:00:00.0000000</embargoDate><copyrightCorrect>true</copyrightCorrect></document></documents><OutputDurs/></rfc1807>
spelling 2020-07-14T12:32:18.7868776 v2 31639 2017-01-18 Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2017-01-18 BMS Journal Article The Lancet Diabetes and Endocrinology 5 5 355 366 22138587 31 5 2017 2017-05-31 10.1016/S2213-8587(17)30085-2 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2020-07-14T12:32:18.7868776 2017-01-18T08:25:28.4206481 Swansea University Medical School Medicine Vanita R Aroda 1 Steve Bain 0000-0001-8519-4964 2 Bertrand Cariou 3 Milivoj Piletič 4 Ludger Rose 5 Mads Axelsen 6 Everton Rowe 7 J Hans DeVries 8 0031639-18012017083234.pdf Aroda2017.pdf 2017-01-18T08:32:34.3230000 Output 999657 application/pdf Accepted Manuscript true 2017-07-23T00:00:00.0000000 true
title Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
spellingShingle Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Steve, Bain
title_short Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
title_full Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
title_fullStr Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
title_full_unstemmed Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
title_sort Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve, Bain
author Steve, Bain
author2 Vanita R Aroda
Steve Bain
Bertrand Cariou
Milivoj Piletič
Ludger Rose
Mads Axelsen
Everton Rowe
J Hans DeVries
format Journal article
container_title The Lancet Diabetes and Endocrinology
container_volume 5
container_issue 5
container_start_page 355
publishDate 2017
institution Swansea University
issn 22138587
doi_str_mv 10.1016/S2213-8587(17)30085-2
college_str Swansea University Medical School
hierarchytype
hierarchy_top_id swanseauniversitymedicalschool
hierarchy_top_title Swansea University Medical School
hierarchy_parent_id swanseauniversitymedicalschool
hierarchy_parent_title Swansea University Medical School
department_str Medicine{{{_:::_}}}Swansea University Medical School{{{_:::_}}}Medicine
document_store_str 1
active_str 0
published_date 2017-05-31T03:44:50Z
_version_ 1718185613848477696
score 10.8434725